drugset / Trial / NCT02288273

Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.

NCT02288273

Phase 4 Completed 239 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindTreatment

Summary

A Randomized, Double-blind, Parallel-group Study to Evaluate the Effect of Bydureon Compared with Placebo on 24-hour Glucose Control in Metformin-treated Patients with Type 2 Diabetes.

Timeline

Start
2014-12
Primary completion
2015-08
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide 2 mg